Zevra Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGZevra Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 64), indicating performance broadly in line with the market. Earnings growth of 130% provides fundamental context to the price action. Investors should exercise caution due to high volatility (59% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.24 | +7.45% | ABOVE |
| 50 SMA | $9.76 | +12.69% | ABOVE |
| 100 SMA | $9.22 | +19.25% | ABOVE |
| 150 SMA | $9.39 | +17.19% | ABOVE |
| 200 SMA | $9.43 | +16.63% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ZVRA in an uptrend right now?
ZVRA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ZVRA overbought or oversold?
ZVRA's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is ZVRA outperforming the market?
ZVRA has a Relative Strength (RS) Rating of 64 out of 99. ZVRA is performing about average compared to the market.
Where is ZVRA in its 52-week range?
ZVRA is trading at $11.00, which is 84% of its 52-week high ($13.16) and 64% above its 52-week low ($7.16).
How volatile is ZVRA?
ZVRA has a Beta of 0.63 and 52-week volatility of 59%. It's less volatile than the S&P 500 - generally more stable.